{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:42:26Z","timestamp":1784018546129,"version":"3.55.0"},"reference-count":42,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2002,3,11]],"date-time":"2002-03-11T00:00:00Z","timestamp":1015804800000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Patients with acquired immunodeficiency syndrome (AIDS)\u2010associated lymphoma\/leukemia have a poor prognosis and are frequently treated with low\u2010intensity therapy. The authors investigated the feasibility and efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper\u2010CVAD), a dose\u2010intensive chemotherapy regimen, in patients with AIDS\u2010associated Burkitt lymphoma\/leukemia, as well as the possible impact of highly active antiretroviral therapy (HAART) in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Thirteen patients with AIDS\u2010associated Burkitt lymphoma (six patients) or leukemia (acute lymphoblastic leukemia; seven patients) were treated with hyper\u2010CVAD alternating with high\u2010dose methotrexate and ara\u2010C for a total of eight cycles. Nine patients received HAART from the start of induction chemotherapy (seven patients) or later in the course of chemotherapy (two patients). The median patient age was 43 years (range, 32\u201355). Nine patients were diagnosed with human immunodeficiency virus (HIV) infection at the time of diagnosis of Burkitt lymphoma\/leukemia; the other 4 patients had been diagnosed with HIV infection for a median of 37 months (range, 18\u2013137) prior to the diagnosis of Burkitt lymphoma\/leukemia. The median absolute CD4 count from the 9 patients with evaluable counts was 77 cells\/\u03bcL (range, 9\u2013544); only one patient had a count &gt; 200\/\u03bcL.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Twelve patients (92%) achieved a complete remission (CR) and one achieved a partial response (PR). Eight patients continued in CR after a median of 31 months (range, 7\u201345) at the time of writing. Five patients were alive and in CR over two years later. The median survival was 12 months, with 48% of patients alive after 2 years. Six of seven patients who received HAART from the start of chemotherapy were alive and in CR after a median of 29 months (range, 7\u201345). The four patients who did not receive HAART died. The regimen was universally myelosuppressive, but the toxicity profiles, recoveries from myelosuppression, and incidences of infectious complications were similar to that of non\u2010HIV patients with Burkitt lymphoma\/leukemia treated with the same regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Hyper\u2010CVAD is an effective regimen for patients with AIDS\u2010associated Burkitt lymphoma\/leukemia, with acceptable toxicity. The combination of hyper\u2010CVAD and HAART is associated with long\u2010term survival in patients with the two diseases, which, until recently, were both considered invariably fatal and almost futile to treat medically. Cancer 2002;94:1492\u20139. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10365<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10365","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T19:10:52Z","timestamp":1030302652000},"page":"1492-1499","source":"Crossref","is-referenced-by-count":134,"title":["Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome\u2010related burkitt lymphoma\/leukemia"],"prefix":"10.1002","volume":"94","author":[{"given":"Jorge","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adan","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Jeha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,3,11]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<645::AID-IJC6>3.0.CO;2-X"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92513-2"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.302.6770.203"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-4-276"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0753-3322(97)86004-0"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.6.1099"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/103.5.561"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.14.6577"},{"key":"e_1_2_5_10_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood.V90.1.313.313_313_322","article-title":"Molecular profile of Epstein\u2010Barr virus in human immunodeficiency virus type 1\u2010related lymphadenopathies and lymphomas","volume":"90","author":"Ometto L","year":"1997","journal-title":"Blood"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1674"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<766::AID-CNCR21>3.0.CO;2-V"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.925"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2461"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.319.7201.23"},{"issue":"1","key":"e_1_2_5_18_2","first-page":"S11","article-title":"Effect of antiretroviral therapy on recent trends in selected cancers among HIV\u2010infected persons","volume":"21","author":"Jones JL","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-199905010-00119"},{"issue":"1","key":"e_1_2_5_20_2","first-page":"21","article-title":"Combination antiretroviral therapy and incidence of AIDS\u2010related malignancies","author":"Buchbinder SP","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.3.381"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non\u2010parametric estimation from incomplete observations","volume":"53","author":"Kaplan EL","year":"1965","journal-title":"J Am Stat Assoc"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1732"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1252"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.1.8.8"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199509000-00010"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.11.3026"},{"key":"e_1_2_5_31_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1200\/JCO.1990.8.4.615","article-title":"Small noncleaved cell lymphoma in adults: superior results for stages I\u2010III disease","volume":"8","author":"Lopez TM","year":"1990","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03470010088036"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706053362304"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90259-R"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/89.4.301"},{"key":"e_1_2_5_36_2","first-page":"A39","article-title":"Chemotherapy for HIV associated non\u2010Hodgkin's lymphoma in combination with highly active antiretroviral therapy (HAART) is not associated with excessive toxicity. Third National AIDS Malignancy Conference, Bethesda, MD, 1999","volume":"21","author":"Ratner L","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02787345"},{"key":"e_1_2_5_38_2","first-page":"829a","article-title":"Efficacy and toxicity of brief duration, high\u2010intensity chemotherapy for small noncleaved cell lymphoma (SNC)\/L\u20103 acute lymphoblastic leukemia (L3ALL): Results of CALGB 9251","volume":"96","author":"Rizzieri DA","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)80013-C"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.11.3601"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.8.2217"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<517::AID-CNCR20>3.0.CO;2-0"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10365","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T09:35:22Z","timestamp":1760261722000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1002\/cncr.10365"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10365","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}